BioPharmaceutical

Stelara, Xarelto, Januvia and Farxiga, which are expected to have biosimilar or generic competition before the end of 2026, could be the first negotiated drugs subject to the policy.

While Amneal cannot wait to jump into unexplored biologics space, it wants to channel its GLP-1 power into the Metsera partnership and service big pharma, and less so on its own generics.

At the J.P. Morgan Healthcare Conference in San Francisco, Sandoz CEO Richard Saynor commented on the “offensively” low pricing for antibiotics in the US – “less than a packet of M&Ms” – while also revealing that the firm has struck a deal with a US PBM for its Samsung Bioepis-partnered Pyzchiva ustekinumab biosimilar to Stelara.

Chairman-designee Andrew Ferguson likely will continue the commission’s investigation of PBMs during the next administration.

Adding to five new clinical trials launched in 2024, Xentria is doubling down on its ambitions in the biosimilars arena with up to six further studies in the coming year.

As Bob Bradway addressed the J.P. Morgan Healthcare Conference in San Francisco, the Amgen chief executive discussed the firm’s biosimilars business – including an ocrelizumab rival to Ocrevus that has just been added to its pipeline. Meanwhile, the CEO also outlined his expectations for imminent biosimilar competition to Amgen’s Prolia and Xgeva denosumab brands.

CHARM Therapeutics' CEO discusses its DragonFold technology, applying AI to cancer drug hunting, and the benefits of its Nobel Prize-winning roots.

Partners Fresenius and Formycon have racked up another pair of approvals for their Otulfi ustekinumab biosimilar rival to Stelara, this time in the UK and Canada.

At the 2025 J.P. Morgan Healthcare Conference, Johnson & Johnson outlined a new competition blueprint for anti-inflammatory biosimilars, going beyond the next blockbuster Tremfya.

In an exclusive interview with Generics Bulletin, Aspargo Labs CEO Michael Demurjian discusses the importance of reformulated liquid oral suspension drugs, while outlining plans to launch a smart device that connects patients and doctors.